Galectin Therapeutics (GALT) Misses Q3 EPS by 14c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.24), $0.14 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
• QNB Corp. sells $254M in securities in portfolio repositioning